



Kavitha Ramchandran

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICES

- **Division of Oncology**

875 Blake Wilbur Dr Rm 2231

MC 6574

Stanford, CA 94305

Tel (650) 724-6668

Fax (650) 498-4696

Bio

BIO

Kavitha Ramchandran MD, graduated with an undergraduate degree in Human Biology from Stanford University, did medical school and residency training in medicine at University of California, San Francisco and completed her fellowship in Medical Oncology and Palliative Medicine at Northwestern University, Chicago. She joined faculty at Stanford University in 2010. Currently she is a Clinical Associate Professor of Medicine in the Division of Oncology.

Dr. Ramchandran is recognized for her contributions as a leader in the integration of palliative and oncology care. Dr. Ramchandran is one of a small number of dual trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research, and novel models of care. She now serves as Stanford Cancer Institute's medical director for PathWell dedicated to improving the quality of life experience for patients with a cancer diagnosis.

In her care of patients Dr. Ramchandran values a deep relationship with the families she cares for. She provides care that is aligned with the patient and family's personal values with the goal of the best quality of life and longevity possible.

Dr. Ramchandran's research focuses on developing care delivery models that incorporate values (patients, family members, and clinicians), as well as novel means of palliative care education. She does research on online education and in patient reported outcomes (PROs). She also is part of an active thoracic oncology trials group recruiting patients for clinical trials using novel therapeutics.

Dr. Ramchandran currently serves as an editor for Cancer.net, the American Society of Clinical Oncology patient and family educational website, the planning committee for the Palliative Care in Oncology Symposium and the National Comprehensive Cancer Network Palliative Care task force. She serves as a clinician in thoracic oncology and in palliative medicine at Stanford Cancer Institute.

CLINICAL FOCUS

- Cancer > Thoracic Oncology

- Palliative Medicine
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Medical Director, Palliative Medicine, Stanford Cancer Institute, (2012- present)

HONORS AND AWARDS

- Honoree, Clinical Effectiveness Leadership Training- CELT (2014)
- Nominee, Medical Residency Teaching Award (2012)
- Honoree, AACR/ASCO: Methods in Clinical Cancer Research (2009)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Faculty, Global Oncology- GO (2015 - present)
- Team member, ASCO Quality Training (2015 - present)
- Palliative Care Best Practices Committee, National Comprehensive Cancer Network (2014 - present)
- Patient and Survivor Care Committee, American Society of Clinical Oncology (2014 - present)
- Team leader, Virtual Learning Collaborative- American Society of Clinical Oncology and American Association of Hospice and Palliative Medicine (2014 - present)
- Faculty, University of Colorado, Academy of Medical Educators (2012 - present)
- Faculty, Global Resource to Advance Cancer Education (2012 - present)
- Board member, Cancer Awareness, Research and Education, San Francisco General Hospital (2002 - present)

PROFESSIONAL EDUCATION

- Fellowship: Northwestern University Hematology and Oncology Fellowship (2009) IL
- Residency: UCSF Internal Medicine Residency (2007) CA
- Board Certification: Hospice and Palliative Medicine, American Board of Internal Medicine (2012)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)
- Medical Education: University of California at San Francisco School of Medicine (2004) CA
- Board Certification, Oncology , Oncology (2009)

COMMUNITY AND INTERNATIONAL WORK

- Global Oncology, TBD

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research focuses on innovative models of care delivery to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.

In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs.

CLINICAL TRIALS

- Crizotinib in Treating Patients With Stage IB-III A Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial), Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-III A Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial), Recruiting
- Genetic Testing in Screening Patients With Stage IB-III A Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial), Recruiting
- Molecular Analysis of Thoracic Malignancies, Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor, Recruiting
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer, Recruiting
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study to Evaluate MEDI4736, Not Recruiting
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- A Prospective Trial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR], Not Recruiting
- A Study of Onartuzumab (MetMab) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Onartuzumab (MetMab) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer, Not Recruiting
- A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC), Not Recruiting
- Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation, Not Recruiting
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026), Not Recruiting
- Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor, Not Recruiting
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas, Not Recruiting
- Erlotinib and Mometinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC), Not Recruiting
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR, Not Recruiting
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations, Not Recruiting
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib, Not Recruiting
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer, Not Recruiting
- MAGE A10####T for Advanced NSCLC, Not Recruiting
- Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer, Not Recruiting
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer, Not Recruiting
- Phase 2 Etipritotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer, Not Recruiting

- Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer, Not Recruiting
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer, Not Recruiting
- Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010], Not Recruiting
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients, Not Recruiting
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer, Not Recruiting
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy, Not Recruiting

PROJECTS

- Model of Care: Integration of palliative care into cancer care using a human centered design approach

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Health Services Research (Masters Program)
- Medicine (Masters Program)
- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial.** *Journal of palliative medicine*
Verma, M., Kosinski, A. S., Volk, M. L., Taddei, T., Ramchandran, K., Bakitas, M., Green, K., Green, L., Navarro, V.
2019; 22 (S1): 34–43
- **Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Gensheimer, M. F., Henry, A., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., Pradhan, P., Banerjee, I., Cho, E., Ramchandran, K., Pollom, E., Koong, A. C., Rubin, et al
2019; 111 (6): 568–74
- **ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.**
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.**
Chaft, J. E., Costa, D., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., Ramchandran, K., Rangachari, D., Huberman, M., Piotrowska, Z., Kris, M. G., Azzoli, C. G., Sequist, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Diehn, M., Wakelee, H. A.
2019; 134: 42–45
- **Health System and Beneficiary Costs Associated With Intensive End-of-Life Medical Services.** *JAMA network open*
Gidwani-Marszowski, R., Asch, S. M., Mor, V., Wagner, T. H., Faricy-Anderson, K., Illarmo, S., Hsin, G., Patel, M. I., Ramchandran, K., Lorenz, K. A., Needleman, J.
2019; 2 (9): e1912161

- **Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., Ramchandran, K. J., Neal, J. W., Wakelee, H. A., Loehrer, P. J.
2019; 137: 71–75
- **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Wakelee, H. A., Diehn, M.
2019
- **Feasibility of a massive online open course to teach skills in primary palliative care for a global audience.**
Kerker, A., DeNofrio, J., Tribett, E., Ramchandran, K.
AMER SOC CLINICAL ONCOLOGY.2018
- **Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data.** *Journal of the National Cancer Institute*
Gensheimer, M. F., Henry, A. S., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., Pradhan, P., Banerjee, I., Cho, E., Ramchandran, K., Pollom, E., Koong, A. C., Rubin, et al
2018
- **Palliative care clinicians and online education in India: a survey.** *BMJ supportive & palliative care*
Kiss-Lane, T., Spruijt, O., Day, T., Lam, V., Ramchandran, K. J., Chan, S., Hsin, G., Vallath, N., Bhatnagar, S., Rajagopal, M. R., Lorenz, K. A.
2018
- **Oncologists' Views on Using Value to Guide Cancer Treatment Decisions** *VALUE IN HEALTH*
Gidwani-Marszowski, R., Nevedal, A. L., Blayney, D. W., Patel, M., Kelly, P., Timko, C., Ramchandran, K., Murrell, S. S., Asch, S. M.
2018; 21 (8): 931–37
- **Quality Of End-Of-Life Care Is Higher In The VA Compared To Care Paid For By Traditional Medicare** *HEALTH AFFAIRS*
Gidwani-Marszowski, R., Needleman, J., Mor, V., Faricy-Anderson, K., Boothroyd, D. B., Hsin, G., Wagner, T. H., Lorenz, K. A., Patel, M. I., Joyce, V. R., Murrell, S. S., Ramchandran, K., Asch, et al
2018; 37 (1): 95–103
- **The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives** *JOURNAL OF PALLIATIVE MEDICINE*
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., Kelly, P. A., Asch, S. M.
2017; 20 (4): 395-403
- **The Appropriate Provision of Primary Versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives.** *Journal of palliative medicine*
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., Kelly, P. A., Asch, S. M.
2016
- **The Current State of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care Survey.** *Journal of the National Comprehensive Cancer Network*
Calton, B. A., Alvarez-Perez, A., Portman, D. G., Ramchandran, K. J., Sugalski, J., Rabow, M. W.
2016; 14 (7): 859-866
- **Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.** *Current treatment options in oncology*
Chandrasekar, D., Tribett, E., Ramchandran, K.
2016; 17 (5): 23-?
- **Integrating Palliative Care Into Oncology: A Way Forward** *CANCER CONTROL*
Ramchandran, K., Tribett, E., Dietrich, B., Von Roenn, J.
2015; 22 (4): 386-395
- **Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.** *Annals of oncology*
Lee, R. T., Ramchandran, K., Sanft, T., Von Roenn, J.
2015; 26 (9): 1838-1845
- **Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.** *Clinical lung cancer*
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., Neal, J. W., Wakelee, H. A.

2014; 15 (3): 202-206

- **A predictive model to identify hospitalized cancer patients at risk for 30-day mortality based on admission criteria via the electronic medical record.** *Cancer*

Ramchandran, K. J., Shega, J. W., von Roenn, J., Schumacher, M., Szmuilowicz, E., Rademaker, A., Weitner, B. B., Loftus, P. D., Chu, I. M., Weitzman, S.
2013; 119 (11): 2074-2080

- **Palliative Care Always** *ONCOLOGY-NEW YORK*

Ramchandran, K., Von Roenn, J. H.
2013; 27 (1): 13-?

- **Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-Small Cell Lung Cancer** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*

Kulesza, P., Ramchandran, K., Patel, J. D.
2011; 136 (2): 228-238

- **Phantom Limb Pain #212** *JOURNAL OF PALLIATIVE MEDICINE*

Ramchandran, K., Hauser, J.
2010; 13 (10): 1285-1286

- **Sex Differences in Susceptibility to Carcinogens** *SEMINARS IN ONCOLOGY*

Ramchandran, K., Patel, J. D.
2009; 36 (6): 516-523

- **My Friend, My Patient** *JOURNAL OF PALLIATIVE MEDICINE*

Ramchandran, K.
2009; 12 (1): 95-96